×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ASND – ascendis pharma a/s - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ASND
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/31
04:01 pm
asnd
Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia
Low
Report
Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia
3/27
05:31 pm
asnd
The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Disorders, and Oncology | DelveInsight
Low
Report
The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Disorders, and Oncology | DelveInsight
3/27
05:31 pm
asnd
The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Disorders, and Oncology | DelveInsight
Low
Report
The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Disorders, and Oncology | DelveInsight
3/18
08:37 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at JPMorgan Chase & Co. from $168.00 to $200.00. They now have an "overweight" rating on the stock.
Medium
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at JPMorgan Chase & Co. from $168.00 to $200.00. They now have an "overweight" rating on the stock.
2/26
03:00 am
asnd
OMass Therapeutics appoints Birgitte Volck as Non-Executive Director
Low
Report
OMass Therapeutics appoints Birgitte Volck as Non-Executive Director
2/25
09:31 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Cantor Fitzgerald from $170.00 to $200.00. They now have an "overweight" rating on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Cantor Fitzgerald from $170.00 to $200.00. They now have an "overweight" rating on the stock.
2/24
04:01 pm
asnd
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
Low
Report
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
2/22
03:30 pm
asnd
Ascendis Pharma A/S (NASDAQ: ASND) was given a new $180.00 price target on by analysts at Morgan Stanley.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) was given a new $180.00 price target on by analysts at Morgan Stanley.
Date
Time
Symbol
Company Name
Action
%Chg
2/12/2025
04:01 pm
ASND
ascendis pharma a/s - american depositary shares
BEAT
Report
13.0%
ascendis pharma a/s - american depositary shares
2/12/2025
04:01 pm
ASND
ascendis pharma a/s - american depositary shares
BEAT
Report
13.0%
ascendis pharma a/s - american depositary shares
2/12/2025
04:01 pm
ASND
ascendis pharma a/s - american depositary shares
BEAT
Report
13.0%
ascendis pharma a/s - american depositary shares
2/12/2025
04:01 pm
ASND
ascendis pharma a/s - american depositary shares
BEAT
Report
13.0%
ascendis pharma a/s - american depositary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/31
04:01 pm
asnd
Form 6-K Ascendis Pharma A/S For: Mar 31
Low
Report
Form 6-K Ascendis Pharma A/S For: Mar 31
3/28
04:01 pm
asnd
Form 6-K Ascendis Pharma A/S For: Mar 28
Low
Report
Form 6-K Ascendis Pharma A/S For: Mar 28
3/20
04:17 pm
asnd
Form 6-K Ascendis Pharma A/S For: Mar 20
Low
Report
Form 6-K Ascendis Pharma A/S For: Mar 20
3/12
04:49 pm
asnd
Form 6-K Ascendis Pharma A/S For: Mar 12
Low
Report
Form 6-K Ascendis Pharma A/S For: Mar 12
3/7
05:03 pm
asnd
Form 144 Ascendis Pharma A/S Filed by: JENSEN MICHAEL WOLFF
Medium
Report
Form 144 Ascendis Pharma A/S Filed by: JENSEN MICHAEL WOLFF
3/6
04:53 pm
asnd
Form 144 Ascendis Pharma A/S Filed by: JENSEN FLEMMING STEEN
Medium
Report
Form 144 Ascendis Pharma A/S Filed by: JENSEN FLEMMING STEEN
3/6
04:52 pm
asnd
Form 144 Ascendis Pharma A/S Filed by: JENSEN MICHAEL WOLFF
Medium
Report
Form 144 Ascendis Pharma A/S Filed by: JENSEN MICHAEL WOLFF
3/5
04:52 pm
asnd
Form 144 Ascendis Pharma A/S Filed by: MIKKELSEN JAN MOLLER
Low
Report
Form 144 Ascendis Pharma A/S Filed by: MIKKELSEN JAN MOLLER
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/20
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Oppenheimer Holdings Inc. from $199.00 to $219.00. They now have an "outperform" rating on the stock.
9.1%
11/18 Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results 6.3%
6/3 Ascendis Pharma A/S (NASDAQ: ASND) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $223.00 price target on the stock, up previously from $219.00. 6.0%
6/14 Form 6-K Ascendis Pharma A/S For: Jun 14 5.5%
11/22 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.3%
12/17 Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Morgan Stanley from $134.00 to $140.00. They now have an "overweight" rating on the stock. 4.6%
12/25 Ascendis Pharma A/S (NASDAQ: ASND) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.1%
10/10 Form 6-K Ascendis Pharma A/S For: Oct 10 3.8%
11/20 Edited Transcript of ASND earnings conference call or presentation 18-Nov-19 9:30pm GMT [Yahoo! Finance News] 3.7%
4/14 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.6%
11/18 Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results 6.3%
6/3 Ascendis Pharma A/S (NASDAQ: ASND) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $223.00 price target on the stock, up previously from $219.00. 6.0%
6/14 Form 6-K Ascendis Pharma A/S For: Jun 14 5.5%
11/22 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.3%
12/17 Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Morgan Stanley from $134.00 to $140.00. They now have an "overweight" rating on the stock. 4.6%
12/25 Ascendis Pharma A/S (NASDAQ: ASND) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.1%
10/10 Form 6-K Ascendis Pharma A/S For: Oct 10 3.8%
11/20 Edited Transcript of ASND earnings conference call or presentation 18-Nov-19 9:30pm GMT [Yahoo! Finance News] 3.7%
4/14 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.6%
TOP News Decliners
6/26
Form 6-K Ascendis Pharma A/S For: Jun 26
-9.8%
9/26 Ascendis Pharma A/S Announces Upcoming Investor Presentation in October -7.5%
4/20 Form 6-K Ascendis Pharma A/S For: Apr 20 -5.8%
5/30 Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -5.4%
8/29 Ascendis Pharma A/S (ASND) Q2 2019 Earnings Call Transcript [The Motley Fool] -5.2%
3/31 Sofinnova Investments Strengthens Executive Team with Promotions of Maha Katabi, PhD, CFA and Sarah Bhagat, PhD -5.0%
11/15 Form 6-K Ascendis Pharma A/S For: Nov 15 -4.2%
7/1 Form 6-K Ascendis Pharma A/S For: Jul 01 -3.9%
4/2 Ascendis Pharma A/S (ASND) Q4 2019 Earnings Call Transcript [The Motley Fool] -3.6%
6/10 Form SC 13G/A Ascendis Pharma A/S Filed by: PRICE T ROWE ASSOCIATES INC /MD/ -3.5%
9/26 Ascendis Pharma A/S Announces Upcoming Investor Presentation in October -7.5%
4/20 Form 6-K Ascendis Pharma A/S For: Apr 20 -5.8%
5/30 Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -5.4%
8/29 Ascendis Pharma A/S (ASND) Q2 2019 Earnings Call Transcript [The Motley Fool] -5.2%
3/31 Sofinnova Investments Strengthens Executive Team with Promotions of Maha Katabi, PhD, CFA and Sarah Bhagat, PhD -5.0%
11/15 Form 6-K Ascendis Pharma A/S For: Nov 15 -4.2%
7/1 Form 6-K Ascendis Pharma A/S For: Jul 01 -3.9%
4/2 Ascendis Pharma A/S (ASND) Q4 2019 Earnings Call Transcript [The Motley Fool] -3.6%
6/10 Form SC 13G/A Ascendis Pharma A/S Filed by: PRICE T ROWE ASSOCIATES INC /MD/ -3.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: